Acasti Pharma Inc.
13F holders, Q3 2024 (September 30)11holders −1
2new positions
3sold out
1famous investor
$3.00avg. 13F price*
At the end of Q3 2024, 11 institutions reported holding Acasti Pharma Inc. in their 13F filings, down 1 from Q2 2024. 2 opened new positions and 3 sold out. The largest holders were AIGH Capital Management LLC ($1.9M), Bank of America Corp. ($1.5M) and Renaissance Technologies ($48K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Acasti Pharma Inc.
- CUSIP
- 00430K865
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $57K |
| Exits | 3 | $2.9M |
All 13F filers, Q2 2024 → Q3 2024: 18,894 shares bought and 1,011,300 shares sold, net −992,406 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| AIGH Capital Management LLC | 0.90% | No change | 641,083 | $1.9M |
| Bank of America Corp. | 0.00% | No change | 494,698 | $1.5M |
| Renaissance Technologies | 0.00% | New | 16,147 | $48K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 2,732 | $8K |
| National Bank of Canada | 0.00% | Reduce -6.3% | 2,719 | $8K |
| Morgan Stanley | 0.00% | No change | 1,882 | $6K |
| Royal Bank of Canada | 0.00% | Reduce -91.8% | 543 | $2K |
| Activest Wealth Management | 0.00% | No change | 104 | $312 |
| UBS Group AG | 0.00% | Reduce -99.6% | 28 | $84 |
| Federation des caisses Desjardins du Quebec | 0.00% | No change | 28 | $84 |
| JPMorgan Chase & Co. | 0.00% | Add +750.0% | 17 | $51 |
"% of holder's portfolio" is ACASTI PHARMA INC's weight in each manager's 13F, not the share of Acasti Pharma Inc. the manager owns.